Lixte Biotechnology (NASDAQ:LIXT) Announces Quarterly Earnings Results

Lixte Biotechnology (NASDAQ:LIXT) issued its quarterly earnings data on Monday. The company reported ($0.27) EPS for the quarter, Zacks reports.

Lixte Biotechnology Stock Performance

Shares of Lixte Biotechnology stock opened at $1.36 on Wednesday. The firm has a 50-day simple moving average of $1.76 and a two-hundred day simple moving average of $1.88. Lixte Biotechnology has a fifty-two week low of $1.02 and a fifty-two week high of $4.40. The company has a market cap of $3.05 million, a P/E ratio of -0.78 and a beta of 0.19.

About Lixte Biotechnology

LIXTE Biotechnology Holdings, Inc, a clinical-stage pharmaceutical company, focuses on identifying targets for cancer drug development, and developing and commercializing cancer therapies. Its lead product candidate, LB-100 is in phase 1b clinical trials combined with Atezolizumab for patients with microsatellite stable metastatic colon cancer.